Skip to main content
Connie Lee Batlevi on Muck Rack

Connie Lee Batlevi

As seen in: Nature, ONCOLOGY journal, Hematology & Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Connie Lee

Contact Connie Lee, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing - Nature Communications

|
By Mark D. Ewalt, Anita S. Bowman, Kseniya Petrova-Drus, Jamal Benhamida, Chad Vanderbilt, Ino de Bruijn, Venkatraman E. Seshan, Debyani Chakravarty, Jae Park, Omar Abdel-Wahab Verified, Wenbin Xiao, Connie Lee Batlevi, Gilles Salles, Raajit Rampal, Anas Younes, Ross Levine, Miguel-Angel Perales, Ahmet Dogan, Michael Berger, A. Rose Brannon, Ahmet Zehir, Jacklyn Casanova, Anoop Balakrishnan Rema
| Nature Verified
Abstract Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor only sequencing assays are limited in their ability to identify definitive somatic variants, which can lead to ambiguity in clinical reporting and patient management.
Open in Who Shared Issue with article?

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma - Leukemia

|
By Ana Alarcon Tomas, Joshua A. Fein, Ellen Fraint, Richard J. Lin, Connie Lee Batlevi, Parastoo B. Dahi, Sergio A. Giralt, Elad Jacoby, M. Lia Palomba, Avichai Shimoni, Gunjan L. Shah, Miguel-Angel Perales, Shalev Fried
| Nature Verified
Abstract Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data guiding management are limited. We describe outcomes and features following CAR-T treatment failure. Of 305 adults who received CD19-CAR-T, 182 experienced disease recurrence or progression (1-year cumulative incidence 63% [95%CI: 57–69]). Of 52 post-CAR-T biopsies evaluated by flow cytometry, 49 (94%) expressed CD19.
Open in Who Shared Issue with article?

OncView™ Podcast: Connie Batlevi, MD, PhD on R/R Follicular Lymphoma Therapy Updates

|
By Matthew Fowler, Connie Lee Batlevi
| ONCOLOGY journal Verified
Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast. As part of the OncView video series, CancerNetwork® spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma.
Open in Who Shared Issue with article?
See all 4 articles